medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-4-67-72medsovet-1854Research ArticleСоциально значимые инфекцииSocially significant infectionsЕВРОПЕЙСКИЕ И АМЕРИКАНСКИЕ РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ ВИЧ-ИНФЕКЦИИTHE EUROPEAN AND AMERICAN GUIDELINES FOR TREATMENT OF HIV INFECTIONЮРИНО. Г.YURINO. G.

д.м.н., профессор

MD, Prof.

ЕФРЕМОВАО. С.EFREMOVAO. S.

к.м.н.

PhD in Medicine

Центральный научно-исследовательский институт эпидемиологии РоспотребнадзораРоссияCentral Research Institute of Epidemiology under RospotrebnadzorRussian Federation201726052017046772Copyright © ЮРИН О.Г., ЕФРЕМОВА О.С., 20172017ЮРИН О.Г., ЕФРЕМОВА О.С.YURIN O.G., EFREMOVA O.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1854

Разрабатываемые в США (DHHS) и Евросоюзе (EACS) рекомендации по лечению больных ВИЧ-инфекцией являются наиболее авторитетными в мире и используются при разработке многих национальных, в том числе российских, рекомендаций. Особенностью рекомендаций Евросоюза и США является строгая научная обоснованность и ориентация на применение в странах с высоким уровнем дохода на душу населения. В процессе развития рекомендаций отмечалась тенденция по обновлению рекомендуемых ими препаратов на все более эффективные, безопасные и удобные в приеме, а также расширения показаний к назначению АРТ вплоть до рекомендации начинать ее всем больным ВИЧ-инфекцией независимо от клинических проявлений и уровня CD4-лимфоцитов. В статье приводится анализ изменений рекомендаций за последние 6 лет, а также последние их версии.

The guidelines for treatment of patients with HIV infection developed in the United States (DHHS) and the European Union (EACS) are the most globally recognised. They are used in the development of many national guidelines, including those in Russia. The guidelines of the European Union and the United States are specific in that they are characterized by high scientific validity and target countries with high income per capita. In the process of the guidelines evolution, they tended to update the recommended drugs with more efficient, safe and easy to use medications; they expanded the list of indications for antiretroviral therapy to the extent that it was recommended to all HIV patients regardless of clinical manifestations and the level of CD4 cells. The article also analyzes the changes that the guidelines underwent over the past 6 years. There are recent versions of the guidelines.

ВИЧ-инфекцияклинические рекомендацииантиретровирусная терапияантиретровирусные препаратывирусная нагрузкаDHHSEACSHIV infectionclinical guidelinesantiretroviral therapyantiretroviral drugsviral loadDHHSEACS.ReferencesCohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med, 2011 Aug 11, 365(6): 493-505. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21767103.Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med, 2011 Aug 11, 365(6): 493-505. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21767103.Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med, 2010 Jul 15, 363(3): 257-265. Available athttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20647201.Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med, 2010 Jul 15, 363(3): 257-265. Available athttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20647201.NSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med, 2015, Jul 20. Available at http://www.ncbi.nlm.nih.gov/pubmed/26192873.NSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med, 2015, Jul 20. Available at http://www.ncbi.nlm.nih.gov/pubmed/26192873.TEMPRANO ANRS Study Group, Danel C, Moh R, et al. A trial of early antiretrovirals and isoniazid preventive therapy in africa. N Engl J Med, 2015 Aug 27, 373(9): 808-822. Available at http://www.ncbi.nlm.nih.gov/pubmed/26193126.TEMPRANO ANRS Study Group, Danel C, Moh R, et al. A trial of early antiretrovirals and isoniazid preventive therapy in africa. N Engl J Med, 2015 Aug 27, 373(9): 808-822. Available at http://www.ncbi.nlm.nih.gov/pubmed/26193126.Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med, 2009 Apr 30, 360(18): 1815-1826. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19339714.Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med, 2009 Apr 30, 360(18): 1815-1826. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19339714.WHO HIV Guidelines. Second Edition. Updated June 2016.WHO HIV Guidelines. Second Edition. Updated June 2016.Scaling up antiretroviral therapy in resource-limited settings. Guidelines for a public health approach. Geneva, World Health Organization, 2002. www.who.int/hiv/pub/prev_care/ScalingUp_E.pdf, accessed 15 May 2013.Scaling up antiretroviral therapy in resource-limited settings. Guidelines for a public health approach. Geneva, World Health Organization, 2002. www.who.int/hiv/pub/prev_care/ScalingUp_E.pdf, accessed 15 May 2013.Vitoria M, Vella S, Ford N. Scaling up antiretroviral therapy in resource-limited settings: adapting guidance and meet the challenges. Current Opinion in HIV and AIDS, 2013, 8: 12– 18.Vitoria M, Vella S, Ford N. Scaling up antiretroviral therapy in resource-limited settings: adapting guidance and meet the challenges. Current Opinion in HIV and AIDS, 2013, 8: 12– 18.Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. Geneva, World Health Organization 2006. http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf, accessed 15 May 2013.Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. Geneva, World Health Organization 2006. http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf, accessed 15 May 2013.Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access: recommendations for a public health approach. 2006 revision. Geneva, World Health Organization, 2006. http://www.who.int/hiv/pub/mtct/antiretroviral/en/index.html, accessed 15 May 2013.Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access: recommendations for a public health approach. 2006 revision. Geneva, World Health Organization, 2006. http://www.who.int/hiv/pub/mtct/antiretroviral/en/index.html, accessed 15 May 2013.Antiretroviral therapy of HIV infection in infants and children: towards universal access. Recommendations for a public health approach. 2006 revision. Geneva, World Health Organization, 2006. http://www.who.int/hiv/pub/guidelines/paediatric020907. pdf, accessed 15 May 2013.Antiretroviral therapy of HIV infection in infants and children: towards universal access. Recommendations for a public health approach. 2006 revision. Geneva, World Health Organization, 2006. http://www.who.int/hiv/pub/guidelines/paediatric020907. pdf, accessed 15 May 2013.Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Geneva, World Health Organization, 2010. http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf, accessed 15 May 2013.Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Geneva, World Health Organization, 2010. http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf, accessed 15 May 2013.Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access: recommendations for a public health approach. 2010 revision. Geneva, World Health Organization, 2010. http://whqlibdoc.who.int/publications/2010/9789241599818_eng.pdf, accessed 15 May 2013.Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access: recommendations for a public health approach. 2010 revision. Geneva, World Health Organization, 2010. http://whqlibdoc.who.int/publications/2010/9789241599818_eng.pdf, accessed 15 May 2013.Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. 2010 revision. Geneva, World Health Organization, 2010. http://whqlibdoc.who.int/publications/2010/9789241599801_eng.pdf, accessed 15 May 2013.Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. 2010 revision. Geneva, World Health Organization, 2010. http://whqlibdoc.who.int/publications/2010/9789241599801_eng.pdf, accessed 15 May 2013.Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. 2013 revision. Geneva, World Health Organization, 2013.Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. 2013 revision. Geneva, World Health Organization, 2013.EACS Guidelines Version 7.1, November 2014.EACS Guidelines Version 7.1, November 2014.EACS Guidelines Version 8,0, October 2015.EACS Guidelines Version 8,0, October 2015.EACS Guidelines Version 8.1, October 2016.EACS Guidelines Version 8.1, October 2016.DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, 2008.DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, 2008.DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, 2011.DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, 2011.Guide for HIV/AIDS Clinical Care. US department of Health and Human Services/ April 2014, 643 p.Guide for HIV/AIDS Clinical Care. US department of Health and Human Services/ April 2014, 643 p.Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents/ Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents — A Working Group of the Office of AIDS Research Advisory Council (OARAC) Downloaded from http://aidsinfo.nih.gov/guidelines on 4/9/2015.Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents/ Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents — A Working Group of the Office of AIDS Research Advisory Council (OARAC) Downloaded from http://aidsinfo.nih.gov/guidelines on 4/9/2015.DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, July 2016.DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, July 2016.Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Ермак Т.Н., Канестри В.Г., Шахгильдян В.И., Козырина Н.В., Буравцова Е.В., Нарсия Р.С., Покровская А.В., Ефремова О.С., Коннов В.В., Куимова У.А., Попова А.А., Хохлова О.Н., Воронин Е.Е., Афонина Л.Ю., Васильева И.А., Зимина В.Н. Национальные рекомендации по диспансерному наблюдению и лечению больных ВИЧ-инфекцией. Эпидемиология и инфекционные болезни, 2016, 6: 72.Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Ермак Т.Н., Канестри В.Г., Шахгильдян В.И., Козырина Н.В., Буравцова Е.В., Нарсия Р.С., Покровская А.В., Ефремова О.С., Коннов В.В., Куимова У.А., Попова А.А., Хохлова О.Н., Воронин Е.Е., Афонина Л.Ю., Васильева И.А., Зимина В.Н. Национальные рекомендации по диспансерному наблюдению и лечению больных ВИЧ-инфекцией. Эпидемиология и инфекционные болезни, 2016, 6: 72.Quinn TC, Wawer MJ, Sewankambo N et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J. Med,. 2000, 342: 921-929.Quinn TC, Wawer MJ, Sewankambo N et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J. Med,. 2000, 342: 921-929.Emery S, Neuhaus JA, Phillips AN et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J. Infect. Dis., 2008, 197(8): 1133-1144.Emery S, Neuhaus JA, Phillips AN et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J. Infect. Dis., 2008, 197(8): 1133-1144.Severe P, Juste MA, Ambroise A et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N. Engl. J. Med., 2010, 363: 257- 265.Severe P, Juste MA, Ambroise A et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N. Engl. J. Med., 2010, 363: 257- 265.Grinsztejn B, Hosseinipour M, Ribaudo H et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect. Dis., 2014, 14(4): 281-290.Grinsztejn B, Hosseinipour M, Ribaudo H et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect. Dis., 2014, 14(4): 281-290.

The authors declare that there are no conflicts of interest present.